Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is Celgene (CELG) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals
by Mitchell Moore
On Monday, Celgene (CELG) announced a sale of its psoriasis drug Otezla for $13.4 billion to Amgen (AMGN). This deal will be all cash and is expected to clear before the end of the year. Celgene's stock climbed 3.2% the day of the announcement and has risen another 0.5% since then.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.
Alexion Wins EC Nod for Soliris in Nervous System Disorder
by Zacks Equity Research
Alexion (ALXN) receives EC approval for the label expansion of lead drug, Soliris, for the indication of rare, devastating disorder of the central nervous system.
Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?
by Zacks Equity Research
Amgen's (AMGN) purchase of Celgene's blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space.
Company News for Aug 27, 2019
by Zacks Equity Research
Companies in the news are: AMGN, PBI, BYND, SRCI, PDCE
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
by Sweta Killa
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene
by Zacks Equity Research
Alexion's (ALXN) shares dip after gaining steam on rumors of a potential acquisition by Amgen last week.
Bristol-Myers Announces Sale of Celgene's Otezla to Amgen
by Zacks Equity Research
Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
by Zacks Equity Research
Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.
Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.
Agios Rides High on Tibsovo Sales Amid Acute Competition
by Zacks Equity Research
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
by Zacks Equity Research
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
Top Stock Reports: Micron, Sinopec, Celgene & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Micron Technology (MU), Sinopec (SNP) and Celgene (CELG).
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
by Zacks Equity Research
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.